Chase Investment Counsel’s Elevance Health ELV Stock Holding History

Chase Investment Counsel’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,089	Closed	-$2.9M	–	101
2019 Q1	$2.9M	Buy	10,089 +3,355	+50%	+$970K	1.49%	29
2018 Q4	$1.77M	Buy	+6,734	New	+$1.85M	1.05%	34

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Chase Investment Counsel's ELV Position: Q2 2019 in Review

Chase Investment Counsel sold out of Elevance Health (ELV) in Q2 2019, closing a stake of 10,089 shares — an estimated $2.9M sold.

Chase Investment Counsel first reported a position in ELV in Q4 2018 and held it in 2 quarters. The position peaked at $2.9M in Q1 2019. 1,030 funds tracked by Wall St. Rank hold ELV as of Q2 2019.

Chase Investment Counsel reported no remaining Elevance Health position as of Q2 2019 after selling out during the quarter.
Chase Investment Counsel sold 10,089 Elevance Health shares in Q2 2019, an estimated $2.9M.
Chase Investment Counsel first reported a position in Elevance Health in Q4 2018 and held it in 2 quarters.
Chase Investment Counsel's Elevance Health position peaked at $2.9M in Q1 2019.
1,030 funds tracked by Wall St. Rank held Elevance Health as of Q2 2019.

Based on Chase Investment Counsel's 13F filing for Q2 2019, filed 7 Aug 2019.